Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00930_DB01017_nanopub.RAVdqFOyukc0qIkj8cpbn5hg3yNq89Tu9Os0tYs-5gg5g#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00930_DB01017 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00930_DB01017 label "DDI between Colesevelam and Minocycline - Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam. [drugbank_resource:DB00930_DB01017]" assertion.
- drugbank_resource:DB00930_DB01017 identifier "drugbank_resource:DB00930_DB01017" assertion.
- drugbank_resource:DB00930_DB01017 title "DDI between Colesevelam and Minocycline - Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam." assertion.
- drugbank:DB00930 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00930_DB01017 assertion.
- drugbank:DB01017 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00930_DB01017 assertion.